Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772408 | 1.00 | KDM1A (0.46) | KDM1AF10PRSS1PRSS2PRSS3 | |
| SCHEMBL2772407 | 1.00 | KDM1A (0.46) | KDM1AF10PRSS1PRSS2PRSS3 | |
| SCHEMBL2772289 | 0.85 | KDM1A (0.43) | KDM1AF10GRIN2BF2 | |
| SCHEMBL9968928 | 0.85 | KDM1A (0.43) | KDM1AF10GRIN2BF2 | |
| SCHEMBL2772286 | 0.85 | KDM1A (0.43) | KDM1AF10GRIN2BF2 | |
| SCHEMBL13146420 | 0.83 | KDM1A (0.42) | KDM1AF10 | |
| SCHEMBL20597674 | 0.81 | RAB9A (0.46) | KDM1APRSS1PRSS2PRSS3F2 | |
| SCHEMBL20597673 | 0.81 | RAB9A (0.46) | KDM1APRSS1PRSS2PRSS3F2 | |
| SCHEMBL408725 | 0.79 | KDM1A (0.43) | KDM1AF10 | |
| SCHEMBL408726 | 0.79 | KDM1A (0.43) | KDM1AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | KDM1A 669/4885F10 3629/4885PRSS1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.